PD-L1 testing based on the SP142 antibody in metastatic triple-negative breast cancer: summary of an expert round-table discussion.

Published on Apr 1, 2021in Future Oncology3.404
· DOI :10.2217/FON-2020-1100
Vicente Peg1
Estimated H-index: 1
(ISCIII: Carlos III Health Institute),
María Ángeles López-García2
Estimated H-index: 2
(ISCIII: Carlos III Health Institute)
+ 6 AuthorsFederico Rojo33
Estimated H-index: 33
Triple-negative breast cancer (TNBC) is more aggressive than other breast cancer subtypes. TNBC is characterized by increased expression of Programmed Death-ligand 1 (PD-L1), a signal used by many tumors to escape the immune response. Expression of PD-L1 is a positive predictor of response to immunotherapy; therefore, it should be investigated in TNBC in order to select patients who may benefit from anti-PD-L1 therapies. While many PD-L1 assays are available, only the VENTANA platform with the anti-PD-L1 (SP142) antibody is licensed as a companion diagnostic device for selecting patients with metastatic/advanced TNBC who are candidates for treatment with atezolizumab. In this article, we provide a summary of an expert round-table discussion about PD-L1 testing, using the SP142 antibody in metastatic TNBC.
#1Yijin Li (Ventana Medical Systems)H-Index: 7
#2Bharathi Vennapusa (Ventana Medical Systems)H-Index: 7
Last. Luciana MolineroH-Index: 33
view all 8 authors...
Metastatic triple-negative breast cancer (mTNBC) is the most aggressive breast cancer subtype. Programmed death ligand 1 (PD-L1) on immune cells (IC) using the VENTANA SP142 assay is linked to improved clinical outcome in atezolizumab plus nab-paclitaxel-treated patients with mTNBC in the IMpassion130 study. The goal of the current study was to evaluate prevalence of VENTANA SP142 PD-L1 assay by anatomic location in 670 histologically confirmed TNBC cases from subjects with metastatic disease sc...
#1Maria Vittoria Dieci (UNIPD: University of Padua)H-Index: 30
#2Vassilena Tsvetkova (UNIPD: University of Padua)H-Index: 4
Last. Pierfranco Conte (UNIPD: University of Padua)H-Index: 84
view all 12 authors...
Abstract Background Tumour infiltrating lymphocytes (TILs) are an established prognostic biomarker for triple-negative breast cancer (TNBC). We evaluated the role of programmed cell-death ligand-1 (PD-L1), CD8 and FOXP3 expression in refining a prognostic model for non-metastatic TNBC beyond classic factors and TILs. Methods Primary tumour samples from 244 early patients with TNBC, all treated with surgery and chemotherapy, were collected. Stromal TILs were evaluated on haematoxylin–eosin slides...
#1Leisha A. EmensH-Index: 54
#2Sylvia AdamsH-Index: 52
Last. Peter SchmidH-Index: 75
view all 16 authors...
Background: Based on findings from IMpassion130, international guidelines now recommend atezolizumab (A) + nab-paclitaxel (nP) for patients (pts) with locally advanced or metastatic TNBC (mTNBC) whose tumours express PD-L1 on tumour-infiltrating immune cells (IC) Here we report prespecified final OS and long-term safety results Methods: The study design and final PFS analysis have been reported (Schmid NEJM 2018) Pts were randomised 1:1 to A + nP or placebo (P) + nP Co-primary endpoints were PFS...
#1Pilar GarridoH-Index: 29
#2Esther CondeH-Index: 19
Last. Fernando López-RíosH-Index: 34
view all 10 authors...
In 2011 the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP) started a joint project to establish guidelines on biomarker testing in patients with advanced non-small-cell lung cancer (NSCLC) based on current evidence. As this field is constantly evolving, these guidelines have been updated, previously in 2012 and 2015 and now in 2019. Current evidence suggests that the mandatory tests to conduct in all patients with advanced NSCLC are for EGFR and BRAF mutat...
#1Hannah SlaterH-Index: 1
Atezolizumab was approved as a first-line treatment for adults with metastatic non-small cell lung cancer whose tumors have high PD-L1 expression, as determined by an FDA approved test, with no EGFR or ALK genomic tumor aberrations.
#1Emily S. Reisenbichler (Yale University)H-Index: 6
#2Gang Han (A&M: Texas A&M University)H-Index: 23
Last. David L. Rimm (Yale University)H-Index: 114
view all 24 authors...
The US Food and Drug Administration (FDA) approved the PD-L1 immunohistochemical assay, SP142, as a companion test to determine eligibility for atezolizumab therapy in patients with advanced triple negative breast cancer (TNBC) but data in lung cancer studies suggest the assay suffers from poor reproducibility. We sought to evaluate reproducibility and concordance in PD-L1 scoring across multiple pathologists. Full TNBC sections were stained with SP142 and SP263 assays and interpreted for percen...
#1Sylvie Lantuejoul (UGA: University of Grenoble)H-Index: 67
#2Ming Sound-Tsao (Princess Margaret Cancer Centre)H-Index: 2
Last. Noriko MotoiH-Index: 31
view all 38 authors...
Abstract The recent development of immune checkpoint inhibitors (ICI) has led to promising advances in the treatment of non-small cell and small cell lung cancer patients with advanced or metastatic disease. Most of ICI target the PD-1/PD-L1 axis with the aim of restoring anti-tumor immunity. Multiple clinical trials for ICI have examined a predictive value of PD-L1 protein expression in tumor cells and/or tumor-infiltrating immune cells by immunohistochemistry (IHC), for which different assays ...
#1Niina LehtoH-Index: 1
#1Peter Schmid (QMUL: Queen Mary University of London)H-Index: 75
#2Hope S. Rugo (UCSF: University of California, San Francisco)H-Index: 108
Last. IMpassion InvestigatorsH-Index: 1
view all 16 authors...
Summary Background Immunotherapy in combination with chemotherapy has shown promising efficacy across many different tumour types. We report the prespecified second interim overall survival analysis of the phase 3 IMpassion130 study assessing the efficacy and safety of atezolizumab plus nab-paclitaxel in patients with unresectable, locally advanced or metastatic triple-negative breast cancer. Methods In this randomised, placebo-controlled, double-blind, phase 3 trial, done in 246 academic centre...
#1Pedro ExmanH-Index: 7
#2Ana C. Garrido-Castro (Harvard University)H-Index: 11
Last. Sara M. Tolaney (Harvard University)H-Index: 56
view all 3 authors...
Purpose of Review Atezolizumab has emerged as a novel treatment in patients with triple-negative breast cancer showing unprecedented survival gain. This breakthrough benefit is exclusively observed in PD-L1-positive patients, but PD-L1 positivity still lacks a reliable definition. In this review, we discuss the current data on PD-L1 testing and its impact on the treatment of patients.
Cited By2
#1Seri Jeong (Hallym University)H-Index: 9
#2Nuri Lee (Hallym University)H-Index: 3
Last. Wonkeun Song (Hallym University)H-Index: 23
view all 5 authors...
Approximately 20% of breast cancer (BC) patients suffer from distant metastasis. The incidence and prevalence rates of metastatic BC have increased annually. Immune checkpoint inhibitors are an emerging area of treatment, especially for metastatic patients with poor outcomes. Several antibody drugs have been developed and approved for companion testing of the programmed death protine-1 (PD-1) axis. We reviewed currently used laboratory methodologies for assays determining PD-1 axis to provide a ...
#1Hugo Arias-Pulido (Dartmouth College)H-Index: 26
#2Ashley Cimino-Mathews (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 32
Last. Eric R. Prossnitz (UNM: University of New Mexico)H-Index: 83
view all 12 authors...
This study evaluated epidemiologic and immune factors associated with pathologic complete response (pCR), breast cancer-specific survival (BCSS) and disease-free survival (DFS) outcomes in inflammatory (IBC) and locally advanced breast cancer (LABC) patients. Tumor-infiltrating lymphocytes (TILs) and CD20+ B-cell frequencies (CD20+), and PD-L1 expression on tumor (PD-L1+carcinoma cells) and immune (PD-L1+TILs) cells were analyzed by immunohistochemistry along with clinicopathologic factors as mo...
#1R. Tyler Hillman (University of Texas MD Anderson Cancer Center)H-Index: 7
#2Douglas I. Lin (Foundation Medicine)H-Index: 18
Last. David M. Gershenson (University of Texas MD Anderson Cancer Center)H-Index: 114
view all 4 authors...
Abstract null null Objective null The objective of this study was to determine the prevalence of predictive biomarkers associated with FDA-approved therapies in molecularly defined adult-type ovarian granulosa cell tumors (aGCTs). null null null Methods null We performed a retrospective cross-sectional cohort study of tumor profiles using the inclusion criteria of molecularly defined (FOXL2 c.C402G positive) aGCTs previously sequenced at Foundation Medicine, Inc. The dataset included coding vari...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.